Plazomicin

Plazomicin
Clinical data
Pronunciation	pla" zoe mye' sin
Trade names	Zemdri
Other names	ACHN-490,; 6'-(Hydroxylethyl)-1-(HABA)-sisomicin
AHFS/Drugs.com	Monograph
MedlinePlus	a618037
License data	US DailyMed: Plazomicin;
Routes of; administration	Intravenous
Drug class	Aminoglycoside
ATC code	J01GB14 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;
CAS Number	1154757-24-0;
PubChem CID	42613186;
DrugBank	DB12615;
ChemSpider	26390008;
UNII	LYO9XZ250J;
KEGG	D10151; as salt: D10655;
ChEMBL	ChEMBL1650559;
PDB ligand	EDS (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID001031303 ;
Chemical and physical data
Formula	C25H48N6O10
Molar mass	592.691 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(=CC[C@H]3N)CNCCO)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CCN)OC[C@]1(C)O;
	InChI InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1; Key:IYDYFVUFSPQPPV-PEXOCOHZSA-N;

Plazomicin, sold under the brand name Zemdri, is an aminoglycoside antibiotic used to treat complicated urinary tract infections.^[1] As of 2019 it is recommended only for those in whom alternatives are not an option.^[1] It is given by injection into a vein.^[1]

Common side effects include kidney problems, diarrhea, nausea, and blood pressure changes.^[1] Other severe side effects include hearing loss, Clostridioides difficile-associated diarrhea, anaphylaxis, and muscle weakness.^[1] Use during pregnancy may harm the baby.^[1] Plazomicin works by decreasing the ability of bacteria to make protein.^[1]

Plazomicin was approved for medical use in the United States in 2018.^[2]^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

^ ^a ^b ^c ^d ^e ^f ^g "Plazomicin Sulfate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 August 2020. Retrieved 10 October 2019.
^ Cite error: The named reference FDA Zemdri 210303 was invoked but never defined (see the help page).
^ "Drug Approval Package: Zemdri (plazomicin)". U.S. Food and Drug Administration. 5 July 2018. Archived from the original on 28 November 2020. Retrieved 25 December 2019.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.